latest update:
[TrialBase DB]

trial summary · NCT07281924

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

A Phase 1b/2 Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of Melphalan Percutaneous Hepatic Perfusion Therapy (HEPZATO KIT™) With Nivolumab and Relatlimab (Opdualag) in Patients With Metastatic Melanoma and Liver Metastasis

Trial record from the TrialBase DB dataset, status RECRUITING, condition Metastatic Melanoma, sponsored by University of Wisconsin, Madison. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07281924phase PHASE1/PHASE2enrollment 15start 2026-11

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients with liver metastasis treated with combination immune checkpoint inhibitor therapy.

Source record: https://clinicaltrials.gov/study/NCT07281924

Facts

registry idNCT07281924
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionMetastatic Melanoma
sponsorUniversity of Wisconsin, Madison
sponsor classOTHER
enrollment15
start date2026-11
primary completion2030-12
completion2030-12
results postednot reported

Conditions

  • Metastatic Melanoma
  • Liver Metastases

Interventions

  • Nivolumab and Relatlimab
  • Melphalan

Countries

  • United States

Intervention types: DEVICE, DRUG

Work with this record